Abstract: SA-PO892

Advanced Glycation End-Products (AGEs) Is Associated with Vascular Calcification and Osteoporosis in CKD Patients

Session Information

  • Mineral Disease: CKD-Bone
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

  • 1203 Mineral Disease: CKD-Bone

Authors

  • Quadros, Kelcia Rosana da Silva, University of Campinas, Campinas, Brazil
  • Caramori, Jacqueline Teixeira, University of São Paulo State, Botucatu, Brazil
  • Jorgetti, Vanda, University of São Paulo, São Paulo, Brazil
  • de Oliveira, Rodrigo B., University of Campinas, Campinas, Brazil
  • Esteves, André Barros Albuquerque, University of Campinas, Campinas, Brazil
  • Franca, Renata Almeida, University of Campinas, Campinas, Brazil
  • Borges, Cynthia Moura, University of Campinas, Campinas, Brazil
  • Carbonara, Cinthia Esbrile Moraes, University of Campinas, Campinas, Brazil
  • Watanabe, Marcela T., University of São Paulo State, Botucatu, Brazil
  • Silva, Maryanne Zilli Canedo, University of São Paulo State, Botucatu, Brazil
  • Antonialli, Fabiana Sampaio, University of Campinas, Campinas, Brazil
  • Roza, Noemi Angelica Vieira, University of Campinas, Campinas, Brazil
Background

Chronic kidney disease (CKD) is associated with mineral and bone disorder (MBD) and cardiovascular disease (CVD). Advanced glycation end-products (AGEs) contribute to these complications and their tissue accumulation can be indirectly measured through skin autofluorescence (sAF) by AGE-ReaderTM.

Methods

To investigate the relations between AGEs intake, tissue and serum AGEs levels with CVD and MBD parameters in CKD patients stages 3-4 and in peritoneal dialysis (PD) , clinical and observational study with healthy subjects (N=37) and patients distributed in 2 groups: CKD stages 3-4 (N=20) and PD (N=28). Clinical and laboratorial parameters, ankle-brachial index (ABI), AGEs-sAF levels and AGEs intake were analyzed. In addition, CKD patients performed hip, hands and lateral abdomen radiographs for investigation of vascular calcification (VC), echocardiogram, bone densitometry and serum carboxymethyllysine (CML) levels assay.

Results

AGEs-sAF was increased in CKD 3-4 and PD patients compared to the healthy subjects (3.05±0.6 vs. 2.4±0.4; p<0.05), despite similar AGEs intake (10.118±4.760 vs. 11.942±5.581; p>0.05). There are no differences in AGEs-sAF levels between CKD3-4 and PD patients (3.04±0.6 vs. 3.06±0.7; p=0.9); AGEs-sAF levels were positively correlated with interventricular septum (R=0.36; p=0.02), age (R=0.56; p=0.0001) and negatively correlated with the T score from bone densitometry (R=-0.36; p=0.03). In addition, AGEs-sAF levels were higher in patients with VC [N=14 (31%)] (3.4±0.5 vs. 2.8±0.5; p=0.01) and among patients with osteoporosis (3.2±0.8 vs. 2.6±0.4; p=0.04).

Conclusion

CKD stages 3-4 and PD patients have increased AGEs-sAF levels, which can be measured non-invasively with the AGE-ReaderTM. AGEs tissue accumulation might play a role on development of VC and osteoporosis in CKD patients.